Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Identifying Patients Treated with Tysabri at Risk for PML

By LabMedica International staff writers
Posted on 06 Mar 2012
The risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) occurs in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn’s disease (CD).

The Stratify JCV antibody enzyme-linked immunosorbent assay (ELISA), when used with other clinical data from the patient, can help health care providers determine the risk of developing PML in MS and CD patients.

Currently, there is no treatment, prevention, or cure for PML, and no certain way to predict who will develop it. More...
This test, in conjunction with other factors, will enable physicians and patients to assess carefully the risks and benefits of continuing Tysabri treatment.

Risk factors have been identified that increase the chance of Tysabri-treated patients developing PML. These include the presence of anti-JCV antibodies, which reflects prior exposure to JCV, treatment with Tysabri for more than 2 years, and treatments with immunosuppressants before receiving Tysabri.

The US Food and Drug Administration (FDA; Silver Spring, MD, USA) permitted marketing of the first test, the Stratify JCV antibody ELISA to help determine risk of patients developing PML.

The Stratify JCV antibody ELISA test is manufactured by Focus Diagnostics (Cypress, CA, USA).

Related Links:
US Food and Drug Administration
Focus Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.